Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Servier
Eli Lilly and Company
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Pfizer
Pfizer
Stanford University
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
Degron Therapeutics Co.
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Ikena Oncology
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Apollomics Inc.
Columbia University
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
National Cancer Institute (NCI)
Universidade Federal de Pernambuco
ABM Therapeutics Corporation
UNICANCER
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Hoffmann-La Roche
Roswell Park Cancer Institute
Celgene
SWOG Cancer Research Network
AHS Cancer Control Alberta
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fox Chase Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
Case Comprehensive Cancer Center